BioCardia, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BioCardia raised net proceeds of approximately $4.9 million via its 'At the Market' facility in Q2 2026. The company received regulatory guidance supporting CardiAMP cell therapy submission to Japan's PMDA in Q4 2026 and FDA confirmation that the CardiAMP HF II trial may support U.S. premarket approval. Cash position improved to $4.1 million (from $2.5 million at Dec 31, 2025), providing anticipated runway into 2027. Net loss improved to $1.6 million (Q2 2026) versus $2.0 million (Q2 2025), driven by lower R&D expenses.
Why this rating
Regulatory milestones (Japan/FDA) + capital raise are material for $9.7M market-cap biotech. Extends runway and de-risks near-term approvals.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.